BINidanib China approved for treatment of scleronopathic interstitial lung disease

Bollinger Ingham today announced his anti-pulmonary fibrosis drug, The ® of Vegat, ® Common name: Nidanib softgels) have been approved by the State Drug Administration of China (NMPA) as the first and only drug currently used in systemic sclerosis-related interstitial pulmonary disease (SSc-ILD), marking a milestone for patients with systemic sclerosis-related interstitial pulmonary disease (SSc-ILD) patients with non-pharmacological treatmentIt is also the second adaptation of The Vigart ® approved in China, and it is worth noting that it is the first global simultaneous submission by Bollinger Ingerheim in China (June 2019), which is only 1.5 months after the APPROVAL of the European Unionthe ® of Vegat has been approved for the treatment of iexclusivetrictive pulmonary fibrosis (IPF) in more than 70 countries (including China) and has been approved in 15 countries for the treatment of systemic sclerosis-related interstitial pulmonary disease (SSc-ILD), and has been shown to slow the progression of the disease by slowing the annual decline in lung function (forced lung capacity)systemic sclerosis (SSc), also known as sclerotic disease, is a rare autoimmune disease that affects multiple organs of the body and cannot be cured, causing scarring (fibrosis) in the skin and internal organs (e.gheart, lungs, digestive tract and kidneys)Scleroderma occurs in the lungs, which can cause interstitial lung disease, known as systemic sclerosis-related interstitial pulmonary disease (SSc-ILD), and about 25% of sclerodertic patients experience significant lung damage within 3 years of diagnosisSSc-ILD is a progressive lung disease in which many patients are asymptomatic in the early stages, but have a poor prognosis and low survival ratesIt is a key driver of death in patients with scleronosis (SSc)Source: